Yuhan Corporation
000100
Clasificación en acciones
#3832
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in... Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
Precio por acción
$63.22
Capitalización bursátil
$4.27B
Cambio (1 día)
-3.12%
Cambio (1 año)
-23.57%
País
KR
Comercio Yuhan Corporation (000100)
Categoría
Healthcare
Ratio P/E de Yuhan Corporation (000100)
Ratio P/E al October 2026 TTM: 29.38
Según los últimos informes financieros y el precio de las acciones de Yuhan Corporation, el P/E actual (TTM) de la empresa es 29.38. Al final de 2024, la empresa tenía un P/E de 126.72.
Historial del ratio P/E de Yuhan Corporation desde 2007 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 29.38 | -32.07% |
| 2025 | 43.25 | -65.87% |
| 2024 | 126.72 | 239.42% |
| 2023 | 37.33 | -13.27% |
| 2022 | 43.05 | 3.71% |
| 2021 | 41.51 | 62.84% |
| 2020 | 25.49 | -63.72% |
| 2019 | 70.26 | 78.46% |
| 2018 | 39.37 | 93.85% |
| 2017 | 20.31 | 68.28% |
| 2016 | 12.07 | -42.96% |
| 2015 | 21.16 | 15.17% |
| 2014 | 18.37 | -14.79% |
| 2013 | 21.56 | 1.25% |
| 2012 | 21.29 | 55.58% |
| 2011 | 13.69 | -4.16% |
| 2010 | 14.28 | -3.91% |
| 2009 | 14.86 | -10.13% |
| 2008 | 16.54 | -16.85% |
| 2007 | 19.89 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 23.30 | -20.70% |
DE
|
|
| 26.92 | -8.39% |
DE
|
|
| 55.58 | 89.16% |
JP
|
|
| 61.13 | 108.07% |
CH
|
|
| 34.87 | 18.69% |
IN
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.